Moss A J
Circulation. 1987 Jun;75(6 Pt 2):V148-53.
The rationale for evaluating the efficacy and safety of calcium entry-blocking drugs to prevent secondary complications in patients after myocardial infarction is presented. The data currently available from postinfarction trials involving verapamil, nifedipine, and diltiazem are critically reviewed, and a comparison of the findings from three major trials of calcium entry-blocking drugs is provided.
本文阐述了评估钙通道阻滞剂预防心肌梗死后患者继发性并发症的疗效和安全性的基本原理。对目前来自涉及维拉帕米、硝苯地平和地尔硫䓬的心肌梗死后试验的现有数据进行了严格审查,并对三项主要钙通道阻滞剂试验的结果进行了比较。